Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 7/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6969656 | 0.78 | HTR2A (0.54) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| Water SCHEMBL6969320 | 0.71 | DRD2 (0.42) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| SCHEMBL8025555 | 0.69 | HTR2A (0.60) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| SCHEMBL6419291 | 0.68 | MEN1 (0.66) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| SCHEMBL13051501 | 0.68 | HTR2A (0.78) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| SCHEMBL4920571 | 0.66 | HTR2A (0.65) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| SCHEMBL5500223 | 0.66 | CHRM1 (0.61) | CHRM1DRD2DRD3CHRM3CHRM2 | |
| SCHEMBL5494740 | 0.66 | SLC6A1 (0.60) | CHRM1DRD2DRD3CHRM3CHRM2 | |
| SCHEMBL5498986 | 0.65 | HTR2A (0.51) | HTR2ACHRM1DRD2DRD3CHRM3 | |
| Hydrochloric Acid SCHEMBL6962296 | 0.65 | CHRM1 (0.60) | CHRM1DRD2DRD3CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| US-20070066570-A1 | Methods for treating sleep disorders | HYPNION, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2004112705-A2 | METHODS FOR TREATING SLEEP DISORDERS | HYPNION, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-6613791-B1 | Treating migraine, neurogenic inflammation, rheumatoid arthritis or insulin resistance | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| US-6239148-B1 | TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, | NOVO NORDISK A/S (DK) | 2001-05-29 | — | — | US | disclosed |
| US-6166009-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| US-6110913-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | NOVO NORDISK A/S (DK) | 2000-08-29 | — | — | US | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6071901-A | TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES | NOVO NORDISK A/S (DK) | 2000-06-06 | — | — | US | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066570-A1 | Methods for treating sleep disorders | HCRTR2, HNMT, HCRTR1 | HTR2A 57/4885CHRM1 460/4885DRD2 366/4885 |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | HTR2A 1379/4885CHRM1 4192/4885DRD2 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.